AR100271A1 - Compuestos de vegfr2 / ang2 - Google Patents
Compuestos de vegfr2 / ang2Info
- Publication number
- AR100271A1 AR100271A1 ARP150101339A ARP150101339A AR100271A1 AR 100271 A1 AR100271 A1 AR 100271A1 AR P150101339 A ARP150101339 A AR P150101339A AR P150101339 A ARP150101339 A AR P150101339A AR 100271 A1 AR100271 A1 AR 100271A1
- Authority
- AR
- Argentina
- Prior art keywords
- ang2
- vegfr2
- compounds
- human
- hepatocellular
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
La presente se refiere a compuestos que se unen al receptor 2 del factor de crecimiento endotelial vascular humano (VEGFR2) y angiopoyetina-2 humana (Ang2), y pueden ser útiles para el tratamiento de cáncer, especialmente tumores sólidos impulsados por VEGFR2 y Ang2, incluyendo cánceres gástrico, carcinoma hepatocelular, de ovarios, colorrectal, de pulmón de células no pequeñas, del tracto biliar, y de mama. Célula; proceso; composición farmacéutica.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462000227P | 2014-05-19 | 2014-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR100271A1 true AR100271A1 (es) | 2016-09-21 |
Family
ID=53264806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150101339A AR100271A1 (es) | 2014-05-19 | 2015-05-04 | Compuestos de vegfr2 / ang2 |
Country Status (21)
Country | Link |
---|---|
US (2) | US9580499B2 (es) |
EP (1) | EP3145955A1 (es) |
JP (1) | JP6074071B2 (es) |
KR (1) | KR20160138312A (es) |
CN (1) | CN106795218A (es) |
AP (1) | AP2016009552A0 (es) |
AR (1) | AR100271A1 (es) |
AU (1) | AU2015264552A1 (es) |
BR (1) | BR112016023635A2 (es) |
CA (1) | CA2945157A1 (es) |
CL (1) | CL2016002891A1 (es) |
EA (1) | EA201691901A1 (es) |
IL (1) | IL248401A0 (es) |
MA (1) | MA40013A (es) |
MX (1) | MX2016015149A (es) |
PE (1) | PE20161397A1 (es) |
PH (1) | PH12016502298A1 (es) |
SG (1) | SG11201608414VA (es) |
TN (1) | TN2016000451A1 (es) |
TW (1) | TW201605894A (es) |
WO (1) | WO2015179168A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR100270A1 (es) * | 2014-05-19 | 2016-09-21 | Lilly Co Eli | Anticuerpos ang2 |
AR103477A1 (es) * | 2015-01-28 | 2017-05-10 | Lilly Co Eli | Compuestos de vegfa / ang2 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
KR101224468B1 (ko) * | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
DE102010003225A1 (de) * | 2010-03-24 | 2011-09-29 | Sennheiser Electronic Gmbh & Co. Kg | In-Ear-Monitor-System und Verfahren zum Steuern eines In-Ear-Monitor-Systems |
TWI426920B (zh) * | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗-vegf/抗-ang-2抗體 |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
KR101981342B1 (ko) * | 2011-03-02 | 2019-05-22 | 로슈 글리카트 아게 | Cea 항체 |
-
2015
- 2015-05-04 AR ARP150101339A patent/AR100271A1/es unknown
- 2015-05-05 TW TW104114317A patent/TW201605894A/zh unknown
- 2015-05-12 PE PE2016002143A patent/PE20161397A1/es not_active Application Discontinuation
- 2015-05-12 AP AP2016009552A patent/AP2016009552A0/en unknown
- 2015-05-12 MX MX2016015149A patent/MX2016015149A/es unknown
- 2015-05-12 CA CA2945157A patent/CA2945157A1/en not_active Abandoned
- 2015-05-12 KR KR1020167031967A patent/KR20160138312A/ko active Search and Examination
- 2015-05-12 CN CN201580025685.8A patent/CN106795218A/zh active Pending
- 2015-05-12 EP EP15724469.0A patent/EP3145955A1/en not_active Withdrawn
- 2015-05-12 BR BR112016023635A patent/BR112016023635A2/pt not_active Application Discontinuation
- 2015-05-12 AU AU2015264552A patent/AU2015264552A1/en not_active Abandoned
- 2015-05-12 US US14/709,511 patent/US9580499B2/en not_active Expired - Fee Related
- 2015-05-12 EA EA201691901A patent/EA201691901A1/ru unknown
- 2015-05-12 SG SG11201608414VA patent/SG11201608414VA/en unknown
- 2015-05-12 TN TN2016000451A patent/TN2016000451A1/en unknown
- 2015-05-12 WO PCT/US2015/030275 patent/WO2015179168A1/en active Application Filing
- 2015-05-12 JP JP2015563167A patent/JP6074071B2/ja not_active Expired - Fee Related
- 2015-05-12 MA MA040013A patent/MA40013A/fr unknown
-
2016
- 2016-10-19 IL IL248401A patent/IL248401A0/en unknown
- 2016-11-14 CL CL2016002891A patent/CL2016002891A1/es unknown
- 2016-11-17 PH PH12016502298A patent/PH12016502298A1/en unknown
-
2017
- 2017-01-17 US US15/407,389 patent/US20170121411A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CL2016002891A1 (es) | 2017-06-23 |
PH12016502298A1 (en) | 2017-02-13 |
SG11201608414VA (en) | 2016-11-29 |
EP3145955A1 (en) | 2017-03-29 |
KR20160138312A (ko) | 2016-12-02 |
TN2016000451A1 (en) | 2018-04-04 |
MA40013A (fr) | 2015-11-26 |
MX2016015149A (es) | 2017-03-07 |
WO2015179168A1 (en) | 2015-11-26 |
CA2945157A1 (en) | 2015-11-26 |
AP2016009552A0 (en) | 2016-11-30 |
JP6074071B2 (ja) | 2017-02-01 |
US9580499B2 (en) | 2017-02-28 |
TW201605894A (zh) | 2016-02-16 |
US20150329626A1 (en) | 2015-11-19 |
US20170121411A1 (en) | 2017-05-04 |
EA201691901A1 (ru) | 2017-04-28 |
BR112016023635A2 (pt) | 2017-10-17 |
AU2015264552A1 (en) | 2016-10-27 |
CN106795218A (zh) | 2017-05-31 |
PE20161397A1 (es) | 2016-12-28 |
IL248401A0 (en) | 2016-11-30 |
JP2016531084A (ja) | 2016-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017023269A2 (pt) | métodos para tratamento de câncer | |
CL2016002359A1 (es) | Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco | |
PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
TN2015000396A1 (en) | Antibody drug conjugates | |
TW201613647A (en) | Compounds and compositions for treating HER2 positive tumors | |
PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
UY36075A (es) | Derivados de tubulisina | |
CY1120123T1 (el) | Μονοκλωνικα αντισωματα κατα της gt468 για τη θεραπεια του καρκινου | |
PH12016502607A1 (en) | Functionalised and substituted indoles as anti-cancer agents | |
PH12016500967A1 (en) | Functionalised and substituted indoles as anti-cancer agents | |
BR112016024789A2 (pt) | métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe | |
AR103477A1 (es) | Compuestos de vegfa / ang2 | |
PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
MX2016009332A (es) | Conjugado de farmaco citotoxico-ligando, metodo de preparacion del mismo y uso del mismo. | |
PH12017500853A1 (en) | Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases | |
AR100271A1 (es) | Compuestos de vegfr2 / ang2 | |
AR100270A1 (es) | Anticuerpos ang2 | |
ES2478793A1 (es) | Composición de nanofilamentos para el tratamiento de tumores | |
UA101396U (ru) | Способ интенсивного лечения злокачественных опухолей | |
UA107884U (uk) | Спосіб інтенсивного лікування раку крові |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |